Neurology

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic PainSilo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain

IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing…

3 months ago
ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT ExclusivityANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

ANI Pharmaceuticals Announces the FDA Approval and Launch of Prucalopride Tablets with 180-Day CGT Exclusivity

PRINCETON, N.J., Jan. 02, 2025 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced that…

3 months ago
Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™

Lab Automation Market to Hit USD 7.71 Billion by 2029 with 6.9% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., Dec. 18, 2024 /PRNewswire/ -- The global lab automation market is expected to reach USD 7.71 Billion by…

3 months ago
Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & DevelopmentNoema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development

Noema Pharma Appoints Volker Knappertz, M.D., as Executive Vice President of Research & Development

BASEL, Switzerland, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Noema Pharma, a clinical-stage biotech company targeting debilitating central nervous system (CNS)…

3 months ago
Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy BodiesCognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

Cognition Therapeutics Announces Positive Results in Phase 2 Study of CT1812 in Dementia with Lewy Bodies

- Improvements Across Measures of Behavior, Function, Cognition and Movement - - Expediting Plans to Advance CT1812 into Late-Stage Trials…

3 months ago
NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational NeurologyNMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational Neurology

NMD Pharma publishes new data on the role of ClC-1 inhibition in Charcot-Marie-Tooth in the Annals of Clinical and Translational…

3 months ago
Bausch Health Responds to Rumors of a Potential Sale of Bausch + LombBausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

Bausch Health Responds to Rumors of a Potential Sale of Bausch + Lomb

LAVAL, QC / ACCESSWIRE / December 12, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch Health"), a…

4 months ago
Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo NordiskEvotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Evotec SE announces first projects for LAB eN(2) drug discovery accelerator with Novo Nordisk

Novo Nordisk and Evotec select three projects from Boston University, Harvard University in collaboration with Mass General Brigham, and Joslin…

4 months ago
New ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General NeurologistsNew ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General Neurologists

New ALS Association-Led Research Finds Specialists Diagnose ALS Twice as Fast as General Neurologists

Groundbreaking thinkALS™ Tool Empowers Providers to Identify and Refer Patients Quicker ARLINGTON, Va., Dec. 10, 2024 /PRNewswire/ -- It can take…

4 months ago
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALSFDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

FDA recommends that Clene leverage additional Neurofilament Light (NfL) data from its three Expanded Access Protocols (EAPs) and the HEALEY…

4 months ago